PFE Stock-Based Compensation
Pfizer · Stock-Based Compensation
PFE Stock-Based Compensation
Latest reported$947.00Mperiod ending
PFE TTM Stock-Based Comp ($0.00 → $947.00M)
TTM stock-based compensation
High-resolution chart · PNG
PFE stock-based compensation history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 947,000,000 | |
| 901,000,000 | |
| 799,000,000 | |
| 751,000,000 | |
| 824,000,000 | |
| 827,000,000 | |
| 877,000,000 | |
| 821,000,000 | |
| 698,000,000 | |
| 640,000,000 | |
| 525,000,000 | |
| 768,000,000 | |
| 752,000,000 | |
| 891,000,000 | |
| 872,000,000 | |
| 1,003,000,000 | |
| 1,161,000,000 | |
| 1,095,000,000 | |
| 1,181,000,000 | |
| 950,000,000 | |
| 881,000,000 | |
| 847,000,000 | |
| 732,000,000 | |
| 738,000,000 | |
| 578,000,000 | |
| 590,000,000 | |
| 718,000,000 | |
| 715,000,000 | |
| 954,000,000 | |
| 952,000,000 | |
| 949,000,000 | |
| 927,000,000 | |
| 831,000,000 | |
| 804,000,000 | |
| 840,000,000 | |
| 754,000,000 | |
| 692,000,000 | |
| 766,000,000 | |
| 691,000,000 | |
| 713,000,000 | |
| 709,000,000 | |
| 650,000,000 | |
| 669,000,000 | |
| 650,000,000 | |
| 652,000,000 | |
| 605,000,000 | |
| 586,000,000 | |
| 529,000,000 | |
| 512,000,000 | |
| 477,000,000 | |
| 523,000,000 | |
| 537,000,000 | |
| 526,000,000 | |
| 540,000,000 | |
| 481,000,000 | |
| 434,000,000 | |
| 422,000,000 | |
| 427,000,000 | |
| 419,000,000 | |
| 401,000,000 | |
| 406,000,000 | |
| 389,000,000 | |
| 405,000,000 | |
| 442,000,000 | |
| 423,000,000 | |
| 416,000,000 | |
| 349,000,000 | |
| 258,000,000 | |
| 266,000,000 | |
| 233,000,000 | |
| 263,000,000 | |
| 263,000,000 | |
| 166,000,000 | |
| 101,000,000 | |
| 141,000,000 | |
| 141,000,000 | |
| 141,000,000 | |
| 141,000,000 | |
| 172,000,000 | |
| 172,000,000 | |
| 172,000,000 | |
| 172,000,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |